The Journal of dermatological treatment最新文献

{"title":"Effective and safe surgery for keratinocyte skin cancer in the elderly over 80 years of age: a single-institution retrospective study of 345 patients over one year.","authors":"Luca D Fontana, Clara Richter, Ramon Lang, Christian Greis, Jürg Hafner","doi":"10.1080/09546634.2025.2461650","DOIUrl":"10.1080/09546634.2025.2461650","url":null,"abstract":"<p><strong>Objectives: </strong>As life expectancy rises and the population continues to age, physicians will be faced with an increasing number of elderly patients with keratinocyte cancer (KC). This study aims to better characterize KC surgery in patients over 80 years of age, with a particular focus on the incidence of postoperative complications.</p><p><strong>Methods: </strong>A retrospective study was conducted on all patients aged 80 years and older who underwent surgery for KC at the University Hospital of Zurich in 2022. Data were collected from operative and postoperative notes within six months after surgery.</p><p><strong>Results: </strong>A total of 565 tumors were removed from 345 patients, consisting mainly of basal cell carcinoma (46.5%) and squamous cell carcinoma (45.8%), including 24.2% clinically large tumors (>2 cm in diameter). A total of 26 complications were recorded, resulting in an overall complication rate of4.6%. Only one patient with a hematoma required surgical revision under local anaesthesia. Four cases of hemorrhage were solved by bed side ligations under local anaesthesia. Of the 26 recorded complications, 15 (58%) concerned wound dehiscence, requiring no further measures. The use of novel oral anticoagulants, lower extremity location, surgical specimen size >2 cm², and flap repair were found to be independent risk factors associated with a statistically higher incidence of complications.</p><p><strong>Conclusions: </strong>This study demonstrated that dermatologic surgery adapted to the geriatric population is relatively safe and effective, even for larger KC of several centimeters in diameter.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2461650"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab.","authors":"Francine Foss, Youn H Kim, Julia Scarisbrick, Oleg Akilov, Robert Ristuccia, Karen Dwyer, Wende Wu, Martine Bagot","doi":"10.1080/09546634.2024.2438794","DOIUrl":"10.1080/09546634.2024.2438794","url":null,"abstract":"<p><strong>Purpose: </strong>Mogamulizumab demonstrated improved outcomes <i>vs.</i> vorinostat across a range of disease and patient characteristics in patients with mycosis fungoides or Sézary syndrome in the MAVORIC trial.</p><p><strong>Materials and methods: </strong>This <i>post-hoc</i> analysis further examined MAVORIC data to assess factors associated with long-term response (ORR >12 months), time to next treatment (TTNT), and impact of concomitant steroid use, lymphopenia, and mogamulizumab-associated rash (MAR) on patient response.</p><p><strong>Results: </strong>A higher proportion of patients achieved ORR lasting ≥4, 6, 8, or 12 months in the mogamulizumab <i>vs.</i> vorinostat arm. Long-term response was also observed in mogamulizumab-treated patients with more advanced disease (stage IVA1 [17/20], B2 blood involvement [18/20], and SS [14/20]). PFS was significantly longer (9.4 <i>vs.</i> 3.1 months; <i>p</i> < 0.0001) in mogamulizumab <i>vs.</i> vorinostat-treated patients taking concomitant steroids. Mogamulizumab-treated patients experienced longer TTNT <i>vs.</i> vorinostat. Lymphopenia and MAR were associated with response to mogamulizumab.</p><p><strong>Conclusions: </strong>MAVORIC demonstrated greater efficacy with mogamulizumab <i>vs.</i> vorinostat in relapsed/refractory patients with CTCL, including those with more advanced disease. Concomitant steroid use improved ORR and PFS but did not impact vorinostat outcomes. Overall responses occurred more frequently in mogamulizumab-treated patients that developed lymphopenia than those that did not. A higher percentage of patients with MAR had an overall response than those without MAR.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2438794"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global onychomycosis management and the challenges of antifungal stewardship.","authors":"Aditya K Gupta, Elizabeth A Cooper, Eckart Haneke, Shari R Lipner, Ditte Marie L Saunte, Chander Grover, Avner Shemer, Bianca M Piraccini, Antonella Tosti, Roderick J Hay","doi":"10.1080/09546634.2025.2526073","DOIUrl":"https://doi.org/10.1080/09546634.2025.2526073","url":null,"abstract":"<p><strong>Purpose: </strong>Onychomycosis, in contrast to other routine superficial dermatophyte infections, is difficult to treat and poor outcomes are not unusual. Few guidelines for onychomycosis management have been published, and these vary considerably from region to region. To meet global antifungal stewardship (AFS) goals, there must be global management guidelines for clinicians to follow in their onychomycosis practice. We aimed to survey current practices for onychomycosis management across a variety of global regions and compare practices to published treatment guidelines, as well as to what degree the management practices may facilitate AFS practices.</p><p><strong>Materials and methods: </strong>An informal literature review was performed to identify regional onychomycosis guidelines. An online survey of our colleagues was distributed to assess current onychomycosis management practices and challenges for comparison with associated regional guidelines. Guidelines and practices were reviewed for adherence to the general AFS principles.</p><p><strong>Results: </strong>Our review of current practices shows that, despite guidelines, identification of the infecting species is often not obtained, and treatment provision does not strictly follow existing guidelines. Lack of laboratory access prevents diagnosis and antifungal susceptibility testing that can help provide targeted treatments and resistance surveillance. Better diagnostic methods are needed as a component to improve management decisions, and provide the reliable monitoring required for effective AFS. Broader clinical testing is needed to address knowledge gaps in onychomycosis therapy. Meeting these challenges must be a priority as antifungal resistance is quickly becoming a worldwide problem.</p><p><strong>Conclusions: </strong>As a reservoir for resistant strains, onychomycosis represents a significant future medical/economic burden. Future onychomycosis guidelines must address the challenge of resource limitations experienced by clinicians, as well as the challenge of balancing the need for AFS principles with the specific needs of onychomycosis therapy.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2526073"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144577430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy prediction model of hematoporphyrin monomethyl ether photodynamic therapy for facial port-wine stains.","authors":"Yuanbo Huang, Wen Ju, Lei Wang, Jun Yang, Mingye Bi","doi":"10.1080/09546634.2025.2531135","DOIUrl":"https://doi.org/10.1080/09546634.2025.2531135","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to identify factors influencing photodynamic therapy (PDT) efficacy in facial port-wine stains (PWS) and to develop a predictive model for treatment outcomes.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 863 patients with facial PWS who had undergone hematoporphyrin monomethyl ether photodynamic therapy (HMME-PDT). Multivariate logistic regression analysis was employed to identify factors influencing efficacy and to construct a nomogram prediction model.</p><p><strong>Results: </strong>A total of 265 patients (30.7%) obtained excellent results while 598 patients (69.3%) did not. The influencing factors identified included age, PWS location, type of PWS, prior treatment history, number of PDT sessions, and vascular and non-vascular features observed <i>via</i> dermoscopy. Receiver operating characteristic curve analysis revealed that the area under the curve for the training and validation cohorts was 0.80 and 0.81, respectively. The calibration curve closely approximated the ideal diagonal line, and the Hosmer-Lemeshow test indicated a good fit for the model in both the training (<i>p</i> = 0.73) and validation cohorts (<i>p</i> = 0.52). Clinical decision curve analysis demonstrated a significantly improved net benefit in both cohorts.</p><p><strong>Conclusions: </strong>Our findings provide dermatologists with an accurate and effective tool for predicting PDT efficacy, facilitating the individualized management of facial PWS.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2531135"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initiation of apremilast treatment decreases prescribed topical therapy amount in patients with psoriasis: a health insurance claims study in Japan.","authors":"Siddharth Chaudhari, Ryuichi Ogawa, Shinichi Imafuku, Hiroshi Saruwatari, Katarzyna Jabłońska, Kathy Tran","doi":"10.1080/09546634.2025.2535686","DOIUrl":"10.1080/09546634.2025.2535686","url":null,"abstract":"<p><strong>Objective: </strong>Effective systemic treatments for psoriasis may reduce the need for topical therapies. The objective of this study was to evaluate changes in topical prescriptions after apremilast initiation.</p><p><strong>Materials and methods: </strong>This retrospective cohort study was performed in the Japanese JMDC health insurance claims database. Adults with psoriasis initiating apremilast between 01/03/2018 and 31/07/2021 and prescribed topical therapies in the previous six months were eligible. Topical therapy prescription was compared between the six months preceding and the six months following apremilast initiation. Data from 319 patients were analyzed.</p><p><strong>Results: </strong>The cumulative amount (grams) of topical therapies prescribed decreased significantly following apremilast initiation from 195.8 ± 236.1 to 162.2 ± 230.9 for steroids (<i>p</i> < 0.001) and from 84.6 ± 89.6 to 77.1 ± 104.6 for vitamin D analogues (<i>p</i> = 0.018). No significant change was observed for fixed-dose combinations (from 133.2 ± 140.0 to 143.4 ± 136.8; <i>p</i> = 0.487) or total topical therapy (from 309.9 ± 272.3 to 301.0 ± 293.0; <i>p</i> = 0.131). For steroids, the reduction was only significant for 'very strong' potency steroids (-33.6 g; <i>p</i> = 0.001). Eighteen patients (6%) discontinued all topical therapy following apremilast initiation and 69 (22%) were prescribed fewer concomitant topical therapies.</p><p><strong>Conclusion: </strong>In conclusion, initiation of systemic apremilast treatment is associated with reduced prescription of topical therapies. Treatment with apremilast may decrease the burden of long-term exposure to topical therapies.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2535686"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144736464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observational study on postoperative JAK inhibitor and corticosteroid therapy following non-cultured epidermal cell suspension transplantation in stable vitiligo patients.","authors":"Yixuan Zhang, Yingying Xu, Wenjun Cui, Xueli Ding, Yuyang Gu, Xuejun Zhang, Min Li","doi":"10.1080/09546634.2025.2540014","DOIUrl":"https://doi.org/10.1080/09546634.2025.2540014","url":null,"abstract":"<p><strong>Objective: </strong>To compare the efficacy and safety of oral corticosteroids and JAK inhibitors as adjunctive treatments following non-cultured epidermal cell suspension (NCES) transplantation in patients with stable vitiligo.</p><p><strong>Methods: </strong>Data were collected from 12 patients with stable vitiligo who underwent NCES transplantation at the Fourth Affiliated Hospital of Soochow University between June 2023 and December 2024. Postoperatively, 36 lesions (from 7 patients) were treated with oral corticosteroids, and 34 lesions (from 5 patients) with upadacitinib, totaling 70 vitiligo lesions evaluated. Clinical efficacy and safety were assessed over a 6-month follow-up period.</p><p><strong>Results: </strong>Both treatment groups showed similar mean repigmentation rates at 6 months. However, the distribution of responses differed. Patients treated postoperatively with JAK inhibitors demonstrated a more polarized pattern, while those receiving corticosteroids showed a more uniform distribution. Anatomical analysis revealed significantly better responses in the face and trunk compared to acral areas in both groups. Notably, JAK inhibitors showed potential advantages in traditional treatment-resistant regions such as the limbs. No serious adverse events were observed in either group.</p><p><strong>Conclusion: </strong>Both JAK inhibitors and corticosteroids appear to be safe and effective postoperative options following NCES. The choice of immunomodulatory strategy may influence repigmentation patterns, especially at different anatomical sites.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2540014"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of high-intensity macro-focused ultrasound for solar lentigo in Chinese patients: a prospective study.","authors":"Ruoxin Pan, Duoduo Gu, Qin Ye, Xiaoqi Meng, Tingwei Liu, Yan Lu, Yang Xu","doi":"10.1080/09546634.2025.2562312","DOIUrl":"10.1080/09546634.2025.2562312","url":null,"abstract":"<p><strong>Background: </strong>Solar lentigo (SL) is a skin disorder associated with photoaging. Studies suggest that high-intensity focused ultrasound can improve UV-induced hyperpigmentation and melasma.</p><p><strong>Objectives: </strong>To evaluate the efficacy and safety of high-intensity macro-focused ultrasound (HI-MFU) for treating SL in Chinese.</p><p><strong>Methods: </strong>This is a prospective, single-center study. Twenty-one patients with SL on both cheeks underwent HI-MFU treatment. Follow-ups at baseline and 2, 4, 6, and 8 weeks post-treatment were conducted to assess improvements using clinical imaging, noninvasive skin assessments, and the Global Esthetic Improvement Scale.</p><p><strong>Results: </strong>The lesional and non-lesional areas showed an increase in L* values at all time points (<i>p</i> < 0.05). Transepidermal water loss values decreased on the left at 8 weeks (<i>p</i> < 0.001). Only two patients experienced transient mild pain and localized edema post-treatment. Two-photon microscopy revealed an uneven two-photon-excited fluorescence signal enhancement surrounding the nuclei of the stratum granulosum and stratum spinosum cells in the SL. At 8 weeks post-treatment, fluorescence signals in both areas were reduced compared to those at baseline.</p><p><strong>Conclusions: </strong>HI-MFU effectively and safely treats SL and enhances skin tightness, lightness, and barrier function, suggesting its ultrasound-toning potential.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2562312"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early response to vunakizumab and its baseline predictors in patients with moderate-to-severe plaque psoriasis: a <i>post hoc</i> analysis of a phase-III trial.","authors":"Yangyiyi Yu, Jinrong Zeng, Jianyun Lu","doi":"10.1080/09546634.2025.2564810","DOIUrl":"https://doi.org/10.1080/09546634.2025.2564810","url":null,"abstract":"<p><strong>Background: </strong>Exploring predictors of early response is meaningful to optimize treatment strategies of patients with psoriasis. However, predictors of early response to vunakizumab remain unidentified.</p><p><strong>Objective: </strong>This study aimed to investigate the early response rates to vunakizumab and identify predictors in patients with moderate-to-severe plaque psoriasis.</p><p><strong>Methods: </strong>Data were derived from a phase-III trial (NCT04839016), and 461 patients with moderate-to-severe plaque psoriasis receiving vunakizumab were included. Early response was defined as ≥50% improvement in the Psoriasis Area Severity Index (PASI 50) by week 2 of treatment.</p><p><strong>Results: </strong>A total of 54.0% of patients achieved early response. The proportion of males with early response (71.1%) was lower than males without that (82.5%) (<i>p</i> = 0.004). Regarding patients who had previous local treatment, the proportion of patients with early response (77.1%) was lower than patients without that (85.4%) (<i>p</i> = 0.024). Male [adjusted odds ratio (OR)=0.558, <i>p</i> = 0.027] and previous local treatment (adjusted OR = 0.586, <i>p</i> = 0.039) independently predicted lower possibility of early response. The nomogram demonstrated good calibration performance (mean absolute error: 0.021) with a limited discriminative ability (C-index: 0.580).</p><p><strong>Conclusion: </strong>Early response rate to vunakizumab was 54.0% in patients with moderate-to-severe plaque psoriasis, where female gender and naïve status to local therapy predicted early response.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2564810"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of a memory metal wire used in dentistry for patients with pincer nail deformity.","authors":"YuRan Liu, Zheyuan Li, Liang Chen","doi":"10.1080/09546634.2025.2566785","DOIUrl":"https://doi.org/10.1080/09546634.2025.2566785","url":null,"abstract":"<p><strong>Background: </strong>Pincer nail deformity is a rare but clinically significant toenail malformation characterized by excessive transverse curvature of the nail plate, often causing pain and functional impairment. Current treatments include surgical and conservative treatments, while existing orthotic devices may cause varying degrees of damage to the nail.</p><p><strong>Objective: </strong>The purpose of this study is to evaluate the efficacy of a memory metal wire (originally used in dentistry) in three subtypes of pincer nail deformity.</p><p><strong>Methods: </strong>A total of 45 patients with various subtypes (Tile-Shaped: 28 cases, Trumpet-Shaped: 10 cases, Fan-Shaped: 7 cases) underwent orthotic treatment. Data collection included demographic questionnaires, Visual Analog Scale (VAS) for pain, and self-reported esthetic satisfaction scores. Pre- and postoperative surveys were analyzed to assess treatment outcomes.</p><p><strong>Results: </strong>Postoperative improvements in VAS scores and self-reported esthetic satisfaction were statistically significant compared to preoperative values (<i>p</i> < 0.05), and no significant differences were observed among subtypes (<i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>The modified pincer nail deformity correction technique using cotton packing, dental resin, and nickel-titanium wire demonstrates universal applicability and favorable therapeutic efficacy across various subtypes, offering a promising clinical approach for pincer nail deformity correction.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2566785"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.","authors":"Nicoletta Bernardini, Annunziata Dattola, Giuseppe Paolo Antonio Gemma, Laura Atzori, Fabio Artosi, Gabriele Biondi, Elena Campione, Aldo Cuccia, Paolo Dessi, Antonella Di Cesare, Martina Dragotto, Alessia Frau, Domenico Giordano, Annamaria Mazzotta, Matteo Megna, Alessandra Michelucci, Maria Antonia Montesu, Cristina Mugheddu, Corinne Orsini, Gianluca Pagnanelli, Salvatore Panduri, Severino Persechino, Luca Potestio, Francesca Prignano, Federica Ricceri, Giuseppe Rizzuto, Emanuele Trovato, Marco Virone, Giovanni Pellacani, Concetta Potenza, Nevena Skroza","doi":"10.1080/09546634.2025.2562311","DOIUrl":"10.1080/09546634.2025.2562311","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic inflammatory disease associated with systemic comorbidities. The Charlson Comorbidity Index (CCI) quantifies comorbidity burden and estimates survival, but its relationship with psoriasis severity and biologic therapies remains underexplored.</p><p><strong>Objective: </strong>To evaluate the association between psoriasis severity and comorbidities, assess the impact of biologic disease-modifying antirheumatic drugs (bDMARDs<i>)</i>, in particular (adalimumab [ADA], risankizumab [RISA], secukinumab [SECU]) on CCI and estimate 10-year survival in psoriatic patients versus controls.</p><p><strong>Methods: </strong>In this multicenter cross-sectional study, 343 psoriasis patients and 343 matched controls from 13 Italian centers were analyzed. CCI scores and comorbidity profiles were stratified by disease severity PASI score [Psoriasis Area and Severity Index] and treatment groups. Survival probabilities were estimated using a predictive model.</p><p><strong>Results: </strong>Psoriasis patients had significantly higher age-adjusted CCI compared to controls (<i>p</i> = 0.021), particularly in severe cases (PASI >10; <i>p</i> = 0.003). Peripheral vascular disease, cerebrovascular disease, and myocardial infarction correlated with disease severity. ADA-treated patients showed lower CCI than those on RISA or SECU (<i>p</i> < 0.05). The estimated 10-year survival did not differ significantly between psoriasis and controls.</p><p><strong>Conclusions: </strong>Psoriasis severity is associated with increased comorbidity burden, highlighting the importance of cardiovascular and metabolic screening. Biologic therapies may differentially affect comorbidity progression, supporting personalized treatment approaches.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2562311"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}